This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-06 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
== History == The All-China Federation of Supply and Marketing Cooperatives traces its origins to the former Central Cooperation Administration, founded by central government in November 1949. The first representative conference of all cooperative workers in China was held in July 1950, and the conference passed documents such as the "Law of the People's Republic of China on Cooperatives (Draft)" (中华人民共和国合作社法（草案）) and the "Articles of Association of the All China Federation of Cooperatives (Draft)" (中华全国合作社联合总社章程（草案）). The All-China Federation of Cooperatives (中华全国合作社联合总社) was established, which unified the leadership and management of supply and marketing, production, fisheries, handicrafts, consumption, and credit cooperatives throughout the whole country. The All-China Federation of Supply and Marketing Cooperatives became a member of the International Cooperative Alliance (ICA) on 14 August 1985.
John's wort), seseli, thlaspi, Daucus carota (carrot), Piper nigrum (black pepper), Piper longum (long pepper), Juniperus (juniper), Syzygium aromaticum (clove), Canary Island wine, Agaricus fruiting bodies Gums, oils and resins: Acaciae (acacia), Styrax benzoin, Gummi arabicum, Sagapeni (wax of an unknown tree, possibly some kind of Ferula), Gummi Opopanax chironium, Gummi Ferula foetida, Commiphora (myrrh), incense, Turpentine from Cyprus, oil from Myristica fragans (nutmeg), Papaver somniverum latex (opium). Animal parts and products: Castoreum, Trochisci Viperarum, Narbonne white honey Mineral substances: Boli armen. verae, Chalciditis (copper salts), Dead Sea bitumen
This compound is used as a component in the production of fire-extinguishing compounds, pharmaceuticals, dyes, pigments, and it is also a basic fertilizer, being a source of ammonia. Ammonium bicarbonate is still widely used in the plastics and rubber industry, in the manufacture of ceramics, in chrome leather tanning, and for the synthesis of catalysts. It is also used for buffering solutions to make them slightly alkaline during chemical purification, such as high-performance liquid chromatography. Because it entirely decomposes to volatile compounds, this allows rapid recovery of the compound of interest by freeze-drying. Relatedly it is also useful as an alkaline buffering agent for analytical LC–MS as its volatility allows it to be rapidly removed automatically from the sample stream in the low pressure spray chambers used by many standard mass spectrometry detectors found at the end of typical LC-MS systems, such as electrospray ionization detectors. This is critical as most mass spectrometry detectors become signal saturated or even damaged with more than a trace amount of ions entering the detector proper at any one time. This issue limits buffering agents and other additives in LC-MS buffers to either extremely trace concentrations or to fairly volatile compounds. In pH ranges from about 7 to 9, ammonium bicarbonate is one of the only options available as the primary buffering agent for most LC-MS buffers. Ammonium bicarbonate is also a key component of the expectorant cough syrup "Senega and Ammonia".
== Professor of physiology == Best succeeded Macleod as professor of physiology at University of Toronto in 1929. During World War II he was influential in establishing a Canadian program for securing and using dried human blood serum. In his later years, he was an adviser to the Medical Research Committee of the United Nations World Health Organization.
Sources: en.wikipedia.org
Type I: Atresia is restricted to the common bile duct. Type II: Atresia of the common hepatic duct. Type III: Atresia involves the most proximal part of the bile ducts (>95% of all cases). In approximately 10% of cases, other anomalies may be associated with biliary atresia. The most common of these syndromic forms is BASM and might include heart lesions, polysplenia, situs inversus, absent venae cavae, and a preduodenal portal vein. Progressive cirrhosis is associated with signs and symptoms of portal hypertension, such as esophagogastric varix bleeding, hypersplenism, hepatorenal syndrome, and hepatopulmonary syndrome. In an Egyptian study, abnormally high levels of aflatoxin B1 and to a lesser extent aflatoxin B2 was found in liver tissue and blood of all neonates with biliary atresia. Aflatoxins may cause extensive damage to the hepatocytes leading to hepatitis and damage to bile ducts causing inflammation, adhesions and final obstruction of bile ducts. The affected neonates have a genetic detoxification defect that does not allow them to detoxify these aflatoxins timely or effectively. The babies have homozygous deficiency of glutathione S transferase (GST) M1. The aflatoxin damaged liver cells and bile duct cells are removed by neutrophil elastase and by involvement of immune system mediators such as CCL-2 or MCP-1, tumor necrosis factor (TNF), interleukin-6 (IL-6), TGF-beta, endothelin (ET), and nitric oxide (NO). Among these, TGF-beta is the most important pro-fibrogenic cytokine that can be seen in progressive cirrhosis.
=== Licensing status === The Orion Corporation originally developed levosimendan and applied for a new drug application in 1998 in the U.S. However the Food and Drug Administration (FDA) requested further trials be conducted and Orion withdrew the application in November 1999. Initially, Orion obtained the approval to market the drug in Sweden in 2000. Since then 60 countries worldwide have approved the drug for acute cardiac care, but it remains unapproved in North America, where it is currently in Phase III development by Tenax Therapeutics for reduction in morbidity in patients with Pulmonary Hypertension derived from Heart Failure with preserved Ejection Faction (PH-HFpEF).
The locant is incorporated into the name of the molecule to remove ambiguity. Thus the molecule is named either pentan-2-one or pentan-3-one, depending on the position of the oxygen atom. Any side chains can be present in the place of oxygen and it can be defined as simply the number on the carbon to which any thing other than a hydrogen is attached.
== Applications == LSF has been demonstrated in an alkaloid toxin (veratridine) and used to introduce an azobenzene group to control the toxin activity with light. The two reported LSF routes may allow introducing other functional groups like radioactive or fluorescent labels.
== Public figures with CMT == US country music singer Alan Jackson. Jackson was definitively diagnosed in his early 50s. US actor Julie Newmar. She played the original Catwoman in the 1960s Batman television series. US Paralympic cyclist Anthony Zahn. He won a bronze medal at the 2008 Beijing Paralympic Games. Jamaica and US fashion designer Rachel Scott, who serves as Creative Director of Proenza Schouler. UK cultural and disability studies academic Professor George McKay. His books include Shakin' All Over: Popular Music and Disability (2014). US Paralympic swimmer Jamal Hill, bronze medallist at the Tokyo 2021 Paralympic Games. US actress Isabelle Tate was reported to have died of a rare variant of the disease in 2025. Irish Paralympic cyclist Eoghan Clifford. US filmmaker and playwright Crystal R. Emery. Known for directing the 2010 documentary The Deadliest Disease in America. Australian wheelchair tennis player Jin Woodman (born 2009)
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.